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BACKGROUND—Brief tools are needed to screen for depressive symptoms among oncology
outpatients.
METHODS—Patients starting radiotherapy for first diagnosis of any tumor completed distress
screening tools including the Patient Health Questionnaire (PHQ-9; PHQ-2), the National
Comprehensive Cancer Network-Distress Thermometer (NCCN-DT), and the Hopkins Symptom
Checklist (HSCL-25). Patients exceeding validated cutoff scores and a systematic sample of
patients who screened negative completed the Structured Clinical Interview for DSM-IV (SCID)
Mood Disorder modules via telephone.
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RESULTS—463 patients from 35 community-based and 2 academic radiation oncology sites
were recruited. Of 455 eligible, 66% were women (n=299) with breast (45%), GI (11%), lung
(10%), gynecologic (6%), or other (27%) cancers. Seventy-five (16.5%) exceeded screening cutoffs for depressive symptoms. Of these, 42 patients completed the SCID. An additional 37 who
screened negative completed the SCID. Among 79 patients completing a SCID, 8 (10.1%) met
criteria for major depression, 2 (2.5%) for Dysthymia, and 6 (7.6%) for Adjustment disorder. The
PHQ-2 demonstrated good psychometric properties for screening for mood disorders, using a cutoff score ≥ 3 (ROC area under the curve=0.83) and was comparable to the PHQ-9 (> 9;
AUC=0.85). The NCCN-DT did not detect depression (AUC=0.59).
CONCLUSION—The PHQ-2 demonstrated good psychometric properties to screen for mood
disorders, which were equivalent to the PHQ-9 and superior to the NCCN-DT. These findings
support using the PHQ-2 to identify patients in need of further assessment for depression, a low
prevalence but clinically significant comorbidity. Findings can inform implementation of distress
screening accreditation standards.
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Precis
Addressing psychosocial needs has been increasingly recognized as an integral component of
quality cancer care and the association between depression and cancer outcomes underscores the
importance of identifying effective strategies for the detection of mood disorder among survivors.
The Personal Health Questionnaire (PHQ)-2 demonstrated good psychometric properties to screen
for mood disorders, which were equivalent to the longer PHQ-9 and superior to the National
Comprehensive Cancer Network Distress Thermometer (NCCN-DT).

Keywords
depression; depression screening; distress; distress screening; mood disorders
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INTRODUCTION
The Institute of Medicine (IOM) report “Cancer care for the whole patient” reviewed the
nature and extent of unmet psychosocial needs among cancer survivors, including negative
consequences for cancer treatment outcomes.1 The IOM report listed “identifying each
patient’s psychosocial health needs” as a requirement to ensure the provision of quality
cancer care. Distress screening has increasingly been identified as an important component
of quality cancer care.2 The National Comprehensive Cancer Network (NCCN) Distress
Cancer. Author manuscript; available in PMC 2018 February 01.
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Management clinical practice guidelines were one of the first to recommend routine distress
screening in oncology care settings.3 The American Society of Clinical Oncology (ASCO)
added psychosocial care including distress screening to the core set of quality indicators as
part of the Quality Oncology Practice Initiative (QOPI) in 2008.4 The American College of
Surgeons Commission on Cancer now requires sites to implement distress screening
programs to meet accreditation standards.5,6
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Distress is broadly defined by the NCCN as “a multifactorial unpleasant emotional
experience of a psychological (cognitive, behavioral, emotional), social and/or spiritual
nature that may interfere with the ability to cope with cancer, its physical symptoms and its
treatment” including depression.3 Estimates of the prevalence of depression among cancer
patients vary considerably depending on the methodology used to define depression and the
sample characteristics (e.g. active treatment, post-treatment surveillance, palliative care). A
recent meta-analysis estimated that 8–24% of cancer patients in non-palliative care settings
experience depression based on pooled mean prevalence estimates.7 Estimates from metaanalytical pooled prevalence based on studies that defined depression using psychiatric
interviews were 25% in palliative care settings and 21% among oncology settings.8 While
depression is less prevalent than anxiety among adults with cancer,8,9 the presence of
depressive symptoms has been associated with poorer cancer outcomes. A meta-analysis of
25 independent studies found a 39% increase in mortality among cancer patients meeting
diagnostic criteria for depression and a 25% increase in mortality risk among those with
depressive symptoms, after controlling for prognostic variables.10 The slope of depressive
symptoms over time was predictive of survival among metastatic breast cancer patients.
Women who reported decreased depression scores over a 12 month period had longer
median survival than women with increased depression.11 The association between
depression and cancer outcomes underscores the importance of implementing effective
strategies for the detection and management of cancer patients with symptoms of depression.
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The primary objective of this trial was to assess the feasibility of a screening procedure to
detect mood disorders, including major depression, among cancer patients receiving
definitive or palliative radiotherapy in community-based radiation oncology settings. The
sensitivity and specificity of commonly used screening measures to detect mood disorders
were evaluated. Secondary objectives of this study were to estimate the prevalence of mood
disorders among cancer patients receiving definitive or palliative radiotherapy, to
characterize the nature of clinical services received to manage depression, and to obtain
patient preferences for and barriers to psychosocial care.
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METHODS
Patients
Eligibility criteria included patients ≥ 21 years of age with their first diagnosis of any cancer
type; cancer stage I-IV, who were within 2 weeks of starting radiotherapy; telephone access;
and fluent in English. Patients currently taking medication for depression or anxiety and
those with a pre-existing diagnosis of depression were eligible. Participants with symptoms
consistent with a psychotic disorder or considered to potentially be at risk for suicide based
on staff clinical judgment were excluded from participating due to ethical considerations.
Cancer. Author manuscript; available in PMC 2018 February 01.
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This study was conducted through the NCI-funded Radiation Therapy Oncology Group
(RTOG) 0841 trial. Participating sites were required to have the NCI designation as a
Community Clinical Oncology Program (CCOP), with the exception of two academic sites
(study investigators’ institutions). This study was approved by each participating site’s
institutional review board. Informed consent was obtained from all participants. Participating
sites were required to complete a questionnaire describing the availability of psychosocial
care at their site. This questionnaire was based on a survey conducted by Jacobsen and
Ransom12 to quantify implementation of National Comprehensive Cancer Network (NCCN)
Distress Management guidelines at NCCN institutions.
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As shown in Figure 1, participants completed depression screening measures at the time of
study enrollment. Staff at participating sites administered the screening and scored
responses. Assessment results and participant’s information were provided to the RTOG
coordinating center. Participants who exceeded clinical cut-off scores on screening measures
completed an in-depth assessment administered by telephone. A systematic sample of
participants who screened negative also completed the telephone-based assessment.
Participants meeting criteria for a mood disorder completed a three month follow-up
telephone-based assessment.
Measures
Socio-demographic characteristics were obtained through patient questionnaire. Functional
status and disease variables, including cancer site, stage and treatment, were extracted from
participant medical records at the time of patient enrollment. Participants completed several
patient-reported outcomes (PROs) measures to screen for depression, described below.

Author Manuscript

Depression Screening Measures
Personal Health Questionnaire (PHQ)—The PHQ-9 is a 9-item scale composed of
questions that correspond to Diagnostic and Statistical Manual of Mental Disorders (DSMIV) diagnostic criteria for a major depressive episode. PHQ-9 scores range from 0–27, a
higher score indicates greater depression. The PHQ-9 has been shown to be efficient and
valid as both a means of identifying depressed patients as well as sensitively measuring
change in symptoms over time.13,14 The two items which comprise the PHQ-2 are contained
within the PHQ-9.15,16 The PHQ-2 consists of the two main criteria for a major depressive
episode, specifically depressed mood and anhedonia with a minimum duration of 2 weeks.
PHQ-2 scores range from 0 to 6.

Author Manuscript

Hopkins Symptom Checklist (HSCL)—The 25-item version17 of the HSCL consists of
a subset of items from the Symptom Checklist-90.18 HSCL-25 scores range from 0–100,
higher scores indicate elevated depression. The HSCL-25 is highly correlated with the 58item version of the HSCL.17 The HSCL-25 has been widely used to screen for depression
among cancer patients17 and has demonstrated excellent reliability (Cronbach’s alpha >.90)
and validity across a variety of general and medical populations.19

Cancer. Author manuscript; available in PMC 2018 February 01.
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National Comprehensive Cancer Network – Distress Thermometer (NCCN-DT)
—The NCCN-DT consists of a single item with instructions to rate distress over the past
week on a scale from 0–10, with higher scores indicating higher distress. The NCCN
recommends using a score of ≥ 4 as a cut-off for distress. The NCCN-DT has demonstrated
good sensitivity and specificity for general distress.3
Participants also completed a 15-item version of the Health Status Questionnaire.20,21
Results are not included in this report.
Telephone-Based Assessment Measure

Author Manuscript

Structured Clinical Interview for DSM-IV—The Structured Clinical Interview
(SCID)22 for DSM-IV was administered via telephone by trained, doctoral-level clinical
psychologists. SCID modules to assess current major depressive episode, dysthymic
disorder, bipolar disorder, and adjustment disorder were administered. Training and
supervision for SCID interviewers followed recommended procedures23 including reviewing
the SCID user’s guide, viewing SCID training videotapes, and rating a pre-recorded
interview administered by an expert interviewer. Study interviewers resolved questions
related to SCID administration, scoring, and interpretation with the study chair.
Administration of the SCID was required within 4 weeks of completion of depression
screening measures.
Participants also completed measures assessing current psychosocial care, preferences for
psychosocial care, and barriers to receive care.
Sample size calculations

Author Manuscript
Author Manuscript

The primary endpoint was the feasibility of implementing the screening procedure. It was
hypothesized that the screening procedure would be demonstrated to be acceptable to
patients and efficient at identifying patients with a mood disorder. The acceptability of the
screening procedure was defined as the percentage of registered patients that successfully
completed the depression screening measures (PHQ-9 and HSCL-25). The efficiency of the
screening procedure was operationalized as the percentage of patients 1) who screened
positive on the PHQ-9 or HSCL-25 and 2) of those, who met DSM-IV criteria for a current
mood disorder based on SCID interview. The screening procedure was defined as
unacceptable if more than 25% of patients failed to complete the PHQ-9 and the HSCL-25.
Screening would be deemed inefficient if less than 34% of patients exceed clinical cut-offs
on the PHQ-9 or the HSCL-25. Based on an estimated 15% attrition rate, screening would
also be deemed inefficient if less than 33% of patients who screened positive for depressive
symptoms were diagnosed with a mood disorder. Given the unacceptable (null hypothesis)
and acceptable (alternative hypothesis) rates listed in Table I, there will be 89% power to
declare the screening tool successful at the 0.07 significance level. It was estimated
screening 400 patients would provide adequate power to evaluate the primary endpoint.
Statistical Methods
Descriptive statistics, such as frequencies, mean, and median were used to display patient
characteristics and screening and interview data. Specificity and sensitivity were assessed for

Cancer. Author manuscript; available in PMC 2018 February 01.
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each screening tool using the SCID interview to determine depression. ROC curves,
specifically area under the curve (AUC), were used to assess the accuracy of each measure
in screening for depression, with an AUC=0.5 indicating the accuracy is similar to pure
chance while a AUC=1.0 indicates perfect accuracy.
Clinical cut-off scores for depression screening measures
An incomplete screen was defined as ≥1 unanswered items on the PHQ-9 or ≥ 3 unanswered
items on the 25-item HSCL-25. A PHQ-9 score ≥10 or a HSCL-25 score ≥44 was
categorized as a positive screen, per established clinical cut-offs.
Managing severe distress and suicidal ideation
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Detailed procedures for the management of patient-reported severe distress or suicidal
ideation were included in the protocol and were approved by local IRBs for participating
sites. All sites were required to provide a document listing on-site and local psychosocial
resources to RTOG Headquarters prior to enrolling any patients, which were maintained on a
password-protected web-site established for this study. This provided on-site staff and
telephone interviewers with immediate access to referral information for distressed
participants. If a participant reported a PHQ-9 score of 20–27 or an HSCL-25 total score of
65–100 during the depression screening, the site was required to document the clinical
response and provide RTOG Headquarters with this documentation. Participant reported
suicidal ideation on the PHQ-9, HSCL-25, or during a SCID interview mandated an
evaluation of risk by site staff or telephone interviewers along with documentation of
participant’s risk and the clinical response, provided to RTOG Headquarters. Telephone
interviewers (SCID interviewers) obtained the participant’s location at the beginning of the
interview in the event the participant reported risk of self-harm, requiring the interviewer to
notify local police. Telephone interviewers had access to the RTOG study-specific web-site
in order to access local referral information as needed during study interviews.
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RESULTS
463 patients were accrued from May 28, 2009 to March 11, 2011 from 37 sites, including 35
CCOP sites and 2 academic cancer centers. Of the 463 participants, 8 were ineligible (6
were DCIS breast cancer and 2 lacked verifying baseline information) and not included in
the analysis. Results are based on 455 participants. Patients’ demographic and medical
characteristics are presented in Table 2.
Feasibility of Implementing the Screening Procedure
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All eligible participants enrolled (n=455) completed all depression screening measures, with
no missing items. The 100% completion rate supports the acceptability of depression
screening. A total of 27 participants (3.7%) reported highly elevated scores on the PHQ-9 or
HSCL-25, requiring a documented clinical response from participating sites. Furthermore,
13 of these 27 patients (2.9%) reported suicidal ideation on the PHQ-9, HSCL-25, or during
a SCID interview, requiring evaluation of risk by site staff or telephone interviewers along
with documentation of participant’s risk and the clinical response.

Cancer. Author manuscript; available in PMC 2018 February 01.
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A total of 75 participants (16.5%) exceeded clinical cut-off scores on depression screening
measures. Of these participants, 35 (46.7%) exceeded the clinical cut-off score on both the
PHQ-9 and HSCL-25, 6 (8.0%) only exceeded the PHQ-9 cut-off, and 34 (45.3%) only
exceeded the cut-off score on the HSCL-25. Descriptive statistics for the PHQ-9, PHQ-2,
HSCL-25, and NCCN-DT are presented in Table 3.
SCID-Diagnosed Mood Disorders
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A total of 79 SCID interviews were administered within 4 weeks of administration of
depression screening measures. SCID interviews were administered to a combined sample of
participants who exceeded depression screening cut-offs (n=42) and a systematic sample of
participants who screened negative (n=37) as seen in Table 4. This represents 52.4% of
interviews required. Missing interviews were due to inability to contact the patient (26%),
patient declining interview (7%), a temporary regulatory hold (12%), and unknown (3%).
Among the 79 participants who completed a SCID, of which 42 were positively screened, 16
met criteria for a mood disorder representing 3.5% of the total study sample. A total of 2
participants (2.5%) met criteria for dysthymia, 6 for an adjustment disorder (7.6%), and 9
for major depression (11.4%). One patient was diagnosed with both major depression and
dysthymia. No patients were diagnosed with mania, hypomania, or a general medical
condition or substance use causing mood-related symptoms.
Sensitivity and specificity of screening measures
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Figure 2 illustrates the sensitivity and specificity of the screening measures in detecting any
mood disorder. The HSCL-25 had the highest sensitivity rate (0.88) but had a lower
specificity rate (0.59). The NCCN-DT has the lowest specificity rate (0.52) with a higher
sensitivity rate of 0.80. The PHQ-9 had sensitivity and specificity rates of 0.69 and 0.79,
respectively, while the PHQ-2 had sensitivity and specificity rates of 0.63 and 0.86,
respectively. As shown in this figure, the PHQ-9 area under the curve (AUC) = 0.85
representing good accuracy in classifying participants as true positives or true negatives. The
PHQ-2 also maintained good accuracy (AUC = 0.83) while being a much shorter tool
compared to the PHQ-9. As shown in Figure 3, a PHQ-2 cut-off of ≥3 or ≥4 maximizes
sensitivity and specificity. The HSCL-25 AUC = 0.80, indicating fair-good accuracy. The
NCCN-DT AOC = 0.59 indicating poor accuracy in classifying patients with regard to the
presence of mood disorders.
Psychosocial Care
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Among the 36 respondents who screened positive on the PHQ-9 or HSCL and completed the
telephone assessment, 66.7% (n=24) reported current care for mood-related concerns.
Oncologists and nurses were the most common providers (32%), followed by mental health
(17.9%), and primary care providers (15.4%). Counseling on-site (89.8%) or off-site
(73.0%), and patient educational materials on managing depression (82.1%) were the most
highly preferred psychosocial services. The most common barriers to psychosocial care
included daily responsibilities (25.6%), physical symptoms (18.2%), feeling that distress
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severity does not warrant psychosocial care (18.0%), and difficulty with time off of work
(15.4%).

DISCUSSION

Author Manuscript

Screening for depression among adults receiving care in community-based radiation
oncology settings is highly feasible, as evidenced by the depression screening measure
completion rate. This finding was observed even among community-based radiotherapy
settings that reportedly do not have distress screening procedures in place. Among a large
sample of participants, a total of 16% of participants exceeded clinical cut-off scores on
standardized depression screening measures which is consistent with prior findings.24 Upon
further assessment, a much lower proportion of patients met DSM-IV criteria for mood
disorders. The current results are consistent with the lower-bound estimates of the
prevalence of depression from a meta-analysis, which calculated the approximate rates of
depression of 5–16% for outpatients.25 Studies that employed a similar methodology in
using expert interviewers to define depression estimated a lower prevalence of depression
and mood disorders.25 Prevalence estimates from RTOG 0841 must be interpreted
cautiously, as this was not designed as an epidemiological study and the low participation
rate (53%) in diagnostic interviews may have led to an underestimation of the prevalence of
mood disorders.

Author Manuscript
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One of the most compelling findings from this trial was the comparability of the PHQ-9 and
the significantly shorter PHQ-2 in accurately categorizing participants with regard to the
presence or absence of a current mood disorder. Both the PHQ-9 and the PHQ-2 have good
accuracy in discriminating cancer patients with a mood disorder from those who do not meet
DSM-IV criteria for a mood disorder, including major depression, dysthymia, and
adjustment disorder. Findings suggest the PHQ-2 can be used to screen for mood disorders,
without sacrificing psychometric properties of the longer PHQ-9, thus minimizing patient
and staff burden. No participants met criteria for bipolar disorder. This finding is timely
given the recent trend to incorporate psychosocial care as a “core” cancer care quality
indicator and the American College of Surgeons Commission on Cancer distress screening
accreditation requirement.5,6 The longer 25-item HSCL did not offer any additional
precision with regard to accurately classifying participants with regard to the presence or
absence of a mood disorder. In contrast, the NCCN-DT has poor accuracy to detect mood
disorders. Using the NCCN-DT to detect mood disorders is akin to using a thermometer to
quantify a patient’s body weight; the NCCN-DT simply does not accurately measure mood
disorders including depression. Previous research has established that the NCCN-DT can
adequately detect clinically significant anxiety,26 however, it research has shown that
depression, not anxiety, is associated with poorer significant outcomes such as survival. Sites
using the NCCN-DT to screen for distress should also administer the PHQ-2 to be sure to
capture clinically significant mood disturbances.
The majority of patients who screened positive for mood-related symptoms (70%) reported
current care for mood-related concerns. The flip side of this finding is that 30% of
participants with elevated symptoms are not currently receiving care. This finding supports
the need to implement systematic distress screening with in-depth assessment and/or referral
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for participants who screen positive. Cancer center-based oncology providers were identified
as the most common sources of psychosocial care, followed by mental health and primary
care providers. This is consistent with a strong preference for on-site counseling as the most
preferred mode of psychosocial care delivery. The most common patient-related barriers to
receiving psychosocial care (daily responsibilities, physical symptom burden) can be
addressed through psychosocial care at the point of cancer care delivery, and through
utilizing non-traditional strategies for psychosocial care delivery such as eHealth and
mHealth approaches.27
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Limitations of this study include the low SCID completion rate among participants who
screened positive. Missing interviews due to inability to contact the participant may
introduce bias, if participants with more severe distress were more difficult to reach. An
additional limitation is the disproportionate representation of breast cancer patients and
women in this sample, potentially limiting generalizability.
In summary, the PHQ-2 is a feasible approach to screen for mood-related symptoms among
cancer patients receiving treatment in community-based radiation oncology practices. Given
the widespread use of radiotherapy to treat cancer, the brief and accurate detection of
patients experiencing mood disorders in radiation oncology settings can lead to the improved
detection and management of distress. The PHQ-2 is an effective tool for identifying cancer
patients with mood disorders, is comparable to the longer PHQ-9, and superior to the widely
used NCCN-DT.
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Figure 1.

Study procedures
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Figure 2.

Receiver Operator Characteristic (ROC) Curve of screening measures
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Figure 3.

ROC Curve of PHQ-2
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Table 1

Author Manuscript

Acceptable and Unacceptable Rates for Screening Procedure

Author Manuscript

Promising
Rates under H1

Discouraging
Rates under Ho

Decision
Rule for
Declaring
Screening
Procedure Success

Patients (Pts) registered to trial

p0=1.00

p0=1.00

--

1) Pts completing questionnaires
(acceptability)

p1=0.80

p1=0.75

76%

2) Pts screening positive (efficiency I)

p2=0.40p1

p2=0.33p1

34%

Pts contacted for diagnostic evaluation

pd=0.85p2

pd=0.85p2

--

3) Pts diagnosed as depressed (efficiency II)

p3=0.40pd

p3=0.33pd

33%

Probability of declaring screening procedure
successful

Power = 0.89
(1 - p3)

α =0.07
(p3)

Note: All 3 decision rules must be met for screening procedure to be considered successful
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Table 2

Author Manuscript

Demographic and medical characteristics
Demographic and medical characteristics (n=455)
Age (years)
Median

59

Min - Max

23 – 88

Q1 – Q3

50 – 69

Gender
Male

156 (34.3%)

Female

299 (65.7%)

Race
American Indian/Alaska Native

2 (0.4%)

Asian

5 (1.1%)

Author Manuscript

Black or African American

66 (14.5%)

More than one race

3 (0.7%)

White

379 (83.3%)

Ethnicity
Hispanic or Latino

15 (3.3%)

Not Hispanic or Latino

431 (94.7%)

Unknown (Individuals not reporting
ethnicity)

9 (2.0%)

Psychotropic Medication
No

392 (86.2%)

Yes

63 (13.8%)

Primary Tumor Site

Author Manuscript

Brain
Breast

5 (1.1%)
206 (45.3%)

Colorectal

23 (5.1%)

GI, other

26 (5.7%)

Gynecologic

27 (5.9%)

Lung

45 (9.9%)

Other

118 (25.9%)

Not specified

5 (1.1%)

Stage

Author Manuscript

I

164 (36.0%)

II

126 (27.7%)

III

85 (18.7%)

IV

42 (9.2%)

Unknown

38 (8.4%)

Palliative Radiotherapy
No

419 (92.1%)

Yes

36 (7.9%)

Chemotherapy
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Demographic and medical characteristics (n=455)

Author Manuscript

No

335 (73.6%)

Yes

120 (26.4%)

Q1 = first quartile; Q3 = third quartile
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Author Manuscript
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Table 3

Author Manuscript

Descriptive characteristics for the PHQ-9, PHQ-2, HSCL-25, and NCCN-DT
Baseline Screening Measures
(n=455)
PHQ-9
Mean

3.5

Std. Dev.

4.3

Positive

41 (9.0%)

Negative

414 (91.0%)

PHQ-2
Mean

0.7

Std. Dev.

1.2

Author Manuscript

Positive

36 (7.9%)

Negative

419 (92.1%)

NCCN-DT
Mean

2.5

Std. Dev.

2.6

Positive

134 (30.5%)

Negative

305 (69.5%)

HSCL-25
Mean

34.9

Std. Dev.

9.7

Positive

69 (15.2%)

Negative

386 (84.8%)
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Table 4

Author Manuscript

Screening Procedure Feasibility
Screening Measures Completed after Registration
Yes

455 (100.0%)

Results on Screening Measures (PHQ-9/HSCL-25)

(n=455)

Positive for depressive symptoms

75 (16.5%)

Negative for depressive symptoms

380 (83.5%)

Number of SCID Interviews Required – All patients*

(n=150)

Interview completed

79 (52.4%)

Not evaluated, patient contacted, declined interview

10 (6.7%)

Not evaluated, temporary IRB hold on contact attempts

18 (12.1%)

Not evaluated, patient unable to be contacted

38 (25.5%)

Unknown†

5 (3.3%)

Author Manuscript

Number of SCID Interviews Required – Negative patients
Interview completed

(n=75)
37 (49.3%)

Not evaluated, patient contacted, declined interview

3 (4.0%)

Not evaluated, temporary IRB hold on contact attempts

11 (14.7%)

Not evaluated, patient unable to be contacted

21 (28.0%)

Unknown

3 (4.0%)

Number of SCID Interviews Required – Positive patients
Interview completed

(n=75)
42 (56.0%)

Not evaluated, patient contacted, declined interview
Not evaluated, temporary IRB hold on contact attempts
Not evaluated, patient unable to be contacted
Unknown

7 (9.3%)
7 (9.3%)
17 (22.7%)
2 (2.7%)

Author Manuscript

Number of SCID Interviews Completed
Patients diagnosed with major depression

(n=79)
16 (20.3%)

*

Systematic sample of 20% of negative screen patients were scheduled for interviews (n=75/380) as well as positive patients (n=75).

SCID: Structured Clinical Interview for DSM-IV
PHQ-9: Patient Health Questionnaire, 9 item
HSCL-25: Hopkins Symptom Checklist, 25 item
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